Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 5/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | NNMT | P40261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3230330 | 0.82 | CXCR2 (0.67) | CXCR2PPARGCA2LMNA | |
| SCHEMBL3225099 | 0.79 | PPARG (0.55) | CXCR2EPHX2NR1H4PPARGMAOB | |
| SCHEMBL6782132 | 0.76 | EPHX2 (0.56) | EPHX2NR1H4PPARGMAOB | |
| SCHEMBL678099 | 0.76 | CA2 (0.70) | EPHX2NR1H4CA2 | |
| SCHEMBL3962896 | 0.76 | LMNA (0.60) | EPHX2NR1H4PPARGLMNAMAPK1 | |
| SCHEMBL5643140 | 0.75 | EPHX2 (0.54) | EPHX2NR1H4HSD17B13PPARGMAOB | |
| SCHEMBL5645307 | 0.75 | EPHX2 (0.58) | EPHX2NR1H4PPARGMAOBNNMT | |
| SCHEMBL3460904 | 0.74 | EPHX2 (0.57) | EPHX2NR1H4PPARGMAOB | |
| SCHEMBL3217701 | 0.74 | CA2 (0.56) | CXCR2PPARGCA2LMNAMAPK1 | |
| SCHEMBL3228209 | 0.73 | CXCR2 (1.00) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | UCB SA (GB) | 2010-03-11 | — | — | US | claimed |
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | UCB SA (GB) | 2010-03-11 | — | — | US | disclosed |
| US-7141590-B2 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | UCB SA (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20050026965-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | DARWIN DISCOVERY LIMITED (GB) | 2005-02-03 | — | — | US | disclosed |
| WO-2002053544-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | DARWIN DISCOVERY LTD. (GB) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | NNT, NAPRT, NNMT | CXCR2 1447/4885EPHX2 882/4885NR1H4 1618/4885 |
| US-20050026965-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | NNT, NAPRT, NNMT | CXCR2 1447/4885EPHX2 882/4885NR1H4 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.